Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ишемическая болезнь сердца и контроль частоты сердечных сокращений
Ишемическая болезнь сердца и контроль частоты сердечных сокращений
Кириченко А.А. Ишемическая болезнь сердца и контроль частоты сердечных сокращений. Consilium Medicum. 2015; 17 (5): 23–25.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Неблагоприятное влияние высокой частоты сердечных сокращений (ЧСС) на течение ишемической болезни сердца (ИБС) хорошо известно. Высокая ЧСС может приводить к несоответствию между возросшей потребностью миокарда в кислороде и способностью к адекватному увеличению коронарного кровотока. Приведен обзор исследований, направленных на изучение возможности урежения ЧСС снижать количество приступов стенокардии у пациентов с ИБС, влиять на риск смерти и сердечно-сосудистых осложнений. Показано, что ограничение ЧСС при стенокардии улучшает самочувствие пациентов, переносимость ими физических нагрузок. Однако не все классы препаратов оказывают влияние на прогноз при ИБС.
Ключевые слова: ишемическая болезнь сердца, частота сердечных сокращений, стенокардия, прогноз.
Key words: ischemic heart disease, heart rate, angina pectoris, prognosis.
Ключевые слова: ишемическая болезнь сердца, частота сердечных сокращений, стенокардия, прогноз.
________________________________________________
Key words: ischemic heart disease, heart rate, angina pectoris, prognosis.
Полный текст
Список литературы
1. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81: 380–6.
2. Aspelund T, Gudnason V, Magnusdottir BT et al. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006. PLoS One 2010; 5 (11): e13957.
3. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010; 100 (4): 684–92.
4. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011; 32: 5–22.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. CIBIS-II Investigators and Committees. Lancet 1999; 353 (9146): 9–13.
6. The βBlocker Pooling Project Research Group. The betablocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
7. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J Suppl 2005; 7(Suppl. H): h7-h15.
8. Стрюк Р.И. Клиническое обоснование применения фиксированной комбинации бисопролола с амлодипином при артериальной гипертонии. Consilium Medicum. 2013; 15 (1): 23–5. / Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial’noi gipertonii. Consilium Medicum. 2013; 15 (1): 23–5. [in Russian]
9. Tardif JC, Ford I, Tendera M et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26 (23): 2529–36.
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091–9.
16. Руднов В.А. Клиническая значимость и возможные пути коррекции гипергликемии при критических состояниях. Consilium Medicum. 2006; 8 (7): 54–61. / Rudnov V.A. Klinicheskaia znachimost’ i vozmozhnye puti korrektsii giperglikemii pri kriticheskikh sostoianiiakh. Consilium Medicum. 2006; 8 (7): 54–61.
17. Белоусов Ю.Б. Клиническая фармакология b-адреноблокаторов. Мат-лы XII науч.-практ. конф. Московской ассоциации кардиологов «b-Адреноблокаторы: современные аспекты применения в кардиологии». М., 1997. / Belousov Iu.B. Klinicheskaia farmakologiia b-adrenoblokatorov. Mat-ly XII nauch.-prakt. konf. Moskovskoi assotsiatsii kardiologov «b-Adrenoblokatory: sovremennye aspekty primeneniia v kardiologii». M., 1997. [in Russian]
18. Горбунов В.В., Алексеев С.А., Зайцев Д.Н. Влияние бета-адреноблокатора третьего поколения – небиволола на вариабельность ритма сердца у больных нестабильной стенокардией. Рос. кардиол. журн. 2001; 6: 55–6. / Gorbunov V.V., Alekseev S.A., Zaitsev D.N. Vliianie beta-adrenoblokatora tret’ego pokoleniia – nebivolola na variabel’nost’ ritma serdtsa u bol’nykh nestabil’noi stenokardiei. Ros. kardiol. zhurn. 2001; 6: 55–6. [in Russian]
19. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999: 1730–7.
20. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
21. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. Engl J Med 1985; 313: 1055–8.
22. Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-bloker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med 2007; 120: 685–92.
23. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
24. Halkin A, Nikolsky E, Aymong E et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol 2003; 92 (Suppl. L): 228L.
25. Kernis SJ, Arguya KJ, Boura J et al. Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site(noSOS), stent PAMI and Air PAMI trials. Circulation 2003; 108 (Suppl. IV): 416–7.
2. Aspelund T, Gudnason V, Magnusdottir BT et al. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006. PLoS One 2010; 5 (11): e13957.
3. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010; 100 (4): 684–92.
4. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011; 32: 5–22.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. CIBIS-II Investigators and Committees. Lancet 1999; 353 (9146): 9–13.
6. The βBlocker Pooling Project Research Group. The betablocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
7. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J Suppl 2005; 7(Suppl. H): h7-h15.
8. Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial’noi gipertonii. Consilium Medicum. 2013; 15 (1): 23–5. [in Russian]
9. Tardif JC, Ford I, Tendera M et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26 (23): 2529–36.
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091–9.
16. Rudnov V.A. Klinicheskaia znachimost’ i vozmozhnye puti korrektsii giperglikemii pri kriticheskikh sostoianiiakh. Consilium Medicum. 2006; 8 (7): 54–61.
17. Belousov Iu.B. Klinicheskaia farmakologiia b-adrenoblokatorov. Mat-ly XII nauch.-prakt. konf. Moskovskoi assotsiatsii kardiologov «b-Adrenoblokatory: sovremennye aspekty primeneniia v kardiologii». M., 1997. [in Russian]
18. Gorbunov V.V., Alekseev S.A., Zaitsev D.N. Vliianie beta-adrenoblokatora tret’ego pokoleniia – nebivolola na variabel’nost’ ritma serdtsa u bol’nykh nestabil’noi stenokardiei. Ros. kardiol. zhurn. 2001; 6: 55–6. [in Russian]
19. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999: 1730–7.
20. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
21. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. Engl J Med 1985; 313: 1055–8.
22. Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-bloker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med 2007; 120: 685–92.
23. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
24. Halkin A, Nikolsky E, Aymong E et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol 2003; 92 (Suppl. L): 228L.
25. Kernis SJ, Arguya KJ, Boura J et al. Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site(noSOS), stent PAMI and Air PAMI trials. Circulation 2003; 108 (Suppl. IV): 416–7.
2. Aspelund T, Gudnason V, Magnusdottir BT et al. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006. PLoS One 2010; 5 (11): e13957.
3. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010; 100 (4): 684–92.
4. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011; 32: 5–22.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. CIBIS-II Investigators and Committees. Lancet 1999; 353 (9146): 9–13.
6. The βBlocker Pooling Project Research Group. The betablocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
7. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J Suppl 2005; 7(Suppl. H): h7-h15.
8. Стрюк Р.И. Клиническое обоснование применения фиксированной комбинации бисопролола с амлодипином при артериальной гипертонии. Consilium Medicum. 2013; 15 (1): 23–5. / Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial’noi gipertonii. Consilium Medicum. 2013; 15 (1): 23–5. [in Russian]
9. Tardif JC, Ford I, Tendera M et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26 (23): 2529–36.
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091–9.
16. Руднов В.А. Клиническая значимость и возможные пути коррекции гипергликемии при критических состояниях. Consilium Medicum. 2006; 8 (7): 54–61. / Rudnov V.A. Klinicheskaia znachimost’ i vozmozhnye puti korrektsii giperglikemii pri kriticheskikh sostoianiiakh. Consilium Medicum. 2006; 8 (7): 54–61.
17. Белоусов Ю.Б. Клиническая фармакология b-адреноблокаторов. Мат-лы XII науч.-практ. конф. Московской ассоциации кардиологов «b-Адреноблокаторы: современные аспекты применения в кардиологии». М., 1997. / Belousov Iu.B. Klinicheskaia farmakologiia b-adrenoblokatorov. Mat-ly XII nauch.-prakt. konf. Moskovskoi assotsiatsii kardiologov «b-Adrenoblokatory: sovremennye aspekty primeneniia v kardiologii». M., 1997. [in Russian]
18. Горбунов В.В., Алексеев С.А., Зайцев Д.Н. Влияние бета-адреноблокатора третьего поколения – небиволола на вариабельность ритма сердца у больных нестабильной стенокардией. Рос. кардиол. журн. 2001; 6: 55–6. / Gorbunov V.V., Alekseev S.A., Zaitsev D.N. Vliianie beta-adrenoblokatora tret’ego pokoleniia – nebivolola na variabel’nost’ ritma serdtsa u bol’nykh nestabil’noi stenokardiei. Ros. kardiol. zhurn. 2001; 6: 55–6. [in Russian]
19. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999: 1730–7.
20. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
21. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. Engl J Med 1985; 313: 1055–8.
22. Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-bloker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med 2007; 120: 685–92.
23. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
24. Halkin A, Nikolsky E, Aymong E et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol 2003; 92 (Suppl. L): 228L.
25. Kernis SJ, Arguya KJ, Boura J et al. Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site(noSOS), stent PAMI and Air PAMI trials. Circulation 2003; 108 (Suppl. IV): 416–7.
________________________________________________
2. Aspelund T, Gudnason V, Magnusdottir BT et al. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006. PLoS One 2010; 5 (11): e13957.
3. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010; 100 (4): 684–92.
4. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011; 32: 5–22.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. CIBIS-II Investigators and Committees. Lancet 1999; 353 (9146): 9–13.
6. The βBlocker Pooling Project Research Group. The betablocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
7. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J Suppl 2005; 7(Suppl. H): h7-h15.
8. Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial’noi gipertonii. Consilium Medicum. 2013; 15 (1): 23–5. [in Russian]
9. Tardif JC, Ford I, Tendera M et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26 (23): 2529–36.
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Fox K, Ford I, Steg PG et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091–9.
16. Rudnov V.A. Klinicheskaia znachimost’ i vozmozhnye puti korrektsii giperglikemii pri kriticheskikh sostoianiiakh. Consilium Medicum. 2006; 8 (7): 54–61.
17. Belousov Iu.B. Klinicheskaia farmakologiia b-adrenoblokatorov. Mat-ly XII nauch.-prakt. konf. Moskovskoi assotsiatsii kardiologov «b-Adrenoblokatory: sovremennye aspekty primeneniia v kardiologii». M., 1997. [in Russian]
18. Gorbunov V.V., Alekseev S.A., Zaitsev D.N. Vliianie beta-adrenoblokatora tret’ego pokoleniia – nebivolola na variabel’nost’ ritma serdtsa u bol’nykh nestabil’noi stenokardiei. Ros. kardiol. zhurn. 2001; 6: 55–6. [in Russian]
19. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999: 1730–7.
20. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
21. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. Engl J Med 1985; 313: 1055–8.
22. Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-bloker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med 2007; 120: 685–92.
23. Harjai KJ, Stone GW, Boura J et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655–60.
24. Halkin A, Nikolsky E, Aymong E et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol 2003; 92 (Suppl. L): 228L.
25. Kernis SJ, Arguya KJ, Boura J et al. Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site(noSOS), stent PAMI and Air PAMI trials. Circulation 2003; 108 (Suppl. IV): 416–7.
Авторы
А.А.Кириченко
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
andrey.apollonovich@yandex.ru
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
andrey.apollonovich@yandex.ru
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
andrey.apollonovich@yandex.ru
________________________________________________
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
andrey.apollonovich@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.